Multiple Sclerosis Treatment: World Drug Market 2012-2022

What are the commercial prospects for multiple sclerosis treatment? Visiongain's report shows you potential drug revenues to 2022. Find data, forecasts and discussions. Discover revenue predictions for multiple sclerosis (MS) treatments at world market, product and national levels to 2022. Our report gives you business research, analysis and data. How will the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri, Extavia and Gilenya perform to 2022? You can find potential revenues. Discover information on disease-modifying agents for MS, the main focus of this work. This study discusses Biogen Idec, Teva, Sanofi, Novartis, Merck Serono, Bayer and other pharmaceutical companies. Receive information you need. What does the future hold? With a strong R&D pipeline, the MS treatment sector has potential to expand. The market will change with the launch of new agents that slow symptom progression and reduce relapse rates. Find R&D trends and commercial opportunities there. Visiongain's report provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work. Revenue forecasts, market shares, developmental trends, discussions and interviews In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 56 tables and charts and three research interviews. Advantages of Multiple Sclerosis Treatment: World Drug Market 2012-2022 for your work Our report gives you the following information and advantages: Find potential revenue to 2022 for the world MS drug market, viewing sales growth Discover revenue forecasts to 2022 for leading MS drugs, assessing commercial potential Assess leading companies, discovering their activities and prospects See revenue forecasts to 2022 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India Review R&D for treating MS, seeing pipeline trends Investigate competition and opportunities influencing the industry and its sales Find out what will stimulate and restrain the industry and market View opinions from our survey, discovering research interviews. There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. We tackle crucial questions on MS treatment, helping you to stay ahead. Gain business research, data and analysis for multiple sclerosis drug treatments Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report

Additional Information

Companies Listed

AB Science SA
Abbott Laboratories
Accentia
Acorda Therapeutics
Actelion
Active Biotech
Adeona
Advancell
Allozyne
Ambrx
Amplimmune
Apitope
Artielle Immunotherapeutics
Athersys
Axxam
Barofold
Baxter Healthcare Corporation
Bayer Schering
Bayhill Therapeutics
Biogen Idec
BioMS Medical Corp
Bionomics
Biopartners
Biotest
Biovista
BTG
Canbex Therapeutics
Celgene
Cell Therapeutics
CenTRion Therapeutics
Charite University
Chiron
Chromos Molecular Systems
CinnaGens
Clinical Data
Cognosci
Compugen
Daiichi Sankyo
Duke University
Elan Pharmaceuticals
European Medicines Agency (EMA)
Evotec
Fast Forward
FivePrime Therapeutics
Food and Drug Administration (FDA, US)
Genentech
GeNeuro
Genmab
Genzyme
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
GTC Biotherapeutics
GW Pharmaceuticals
Hard to Treat Diseases (HTDS)
Hemispherx Biopharma
Henry Ford Health System
Hospices Civils de Lyon
Howard Florey Institute
Immune Tolerance Network
Innate Therapeutics
International Multiple Sclerosis Management Practice
Jewish General Hospital Lady David Institute
Kineta
Landsteiner
LTKFarma
McGill University
MediciNova
Merck KGaA
Merck Serono
Momenta Pharmaceuticals
Multiple Sclerosis Research Center of New York
Multiple Sclerosis Trust (UK)
Mylan
Natco Pharma
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Allergy and Infectious Diseases
National Institute of Neurological Disorders and Strokes
National Institutes of Health Clinical Centre
National Multiple Sclerosis Society (US)
Neurotec Pharma
Northwestern University
Novartis
NovImmune
Nuron
Ono Pharmaceutical Co.
Opexa Therapeutics
Oregon Health & Science University
Peninsula College of Medicine and Dentistry, Clinical Neurology Research and Trials Group
Peptimmune
Pfizer
Pluristem Therapeutics
Prescription Solutions
Probiomed
ProtAffin
Provid Pharmaceuticals
Purdue University
Receptopharm
Receptos
RegeneRX
Roche
Rush University Medical Centre
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co
ScreeningPort
Slavica Biochem
Stem Cell Network (Canada)
Stem Cell Therapeutics
SUNY Downstate Medical Centre
SuppreMol
Teva Pharmaceutical Industries
The Gladstone Institutes
Trophos
UC Boulder
United States National Multiple Sclerosis Society
University of Calgary
University of California Davis
University of California San Francisco
University of Louisville
University of Sao Paolo
Uppsala University
World Health Organization (WHO)